BETAXOLOL tablet, film coated

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Buy It Now

Active ingredient:

BETAXOLOL HYDROCHLORIDE (UNII: 6X97D2XT0O) (BETAXOLOL - UNII:O0ZR1R6RZ2)

Available from:

Golden State Medical Supply, Inc.

INN (International Name):

BETAXOLOL HYDROCHLORIDE

Composition:

BETAXOLOL HYDROCHLORIDE 10 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Betaxolol tablets, USP is indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly thiazide-type diuretics. Betaxolol tablets, USP is contraindicated in patients with known hypersensitivity to the drug. Betaxolol tablets, USP is contraindicated in patients with sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see Warnings).

Product summary:

Betaxolol Tablets, USP are available as follows: Betaxolol Tablets, USP 10 mg: (Each tablet contains 10 mg betaxolol HCl equivalent to 8.94 mg betaxolol) are as white, round, film-coated biconvex tablets, debossed "k" above bisect "13" on one side and plain on the other. Bottles of 100, NDC 60429-753-01 Betaxolol Tablets, USP 20 mg: (Each tablet contains 20 mg betaxolol HCl equivalent to 17.88 mg betaxolol) are as white, round, film-coated biconvex tablets, debossed "K" above "14" on one side and plain on the other. Bottles of 100, NDC 60429-754-01 Store at 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in a tight container as defined in the USP, with a child-resistant closure (as required). Manufactured by: KVK-TECH, INC. 110 Terry Drive Newtown, PA 18940 ID # 006037/09 04/2020 Manufacturer’s Code: 10702 Marketed/Packaged by: GSMS, Inc. Camarillo, CA USA 93012

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

                                BETAXOLOL- BETAXOLOL TABLET, FILM COATED
GOLDEN STATE MEDICAL SUPPLY, INC.
----------
BETAXOLOL TABLETS, USP
DESCRIPTION:
Betaxolol hydrochloride is a ß
-selective (cardioselective) adrenergic receptor blocking
agent available as 10-mg and 20-mg tablets for oral administration.
Betaxolol
hydrochloride is chemically described as 2-propanol, 1-
[4-[2-(cyclopropylmethoxy)
ethyl] phenoxy]-3-[(1-methylethyl) amino]-, hydrochloride, (±)-. It
has the following
chemical structure:
Each tablet for oral administration contains 10 mg or 20 mg of
betaxolol hydrochloride
equivalent to 8.94 mg or 17.88 mg of betaxolol respectively. In
addition, each tablet
contains the following inactive ingredients, carnauba wax,
hypromellose, anhydrous
lactose, microcrystalline cellulose, polyethylene glycol, polysorbate
80, pregelatinized
starch, sodium starch glycolate, stearic acid and titanium dioxide.
Betaxolol hydrochloride is a water-soluble white crystalline powder
with a molecular
formula of C
H
NO
•HCl and a molecular weight of 343.9. It is freely soluble in
water, ethanol, chloroform, and methanol, and has a pKa of 9.4.
CLINICAL PHARMACOLOGY:
Betaxolol is a ß
-selective (cardioselective) adrenergic receptor blocking agent that
has
weak membrane-stabilizing activity and no intrinsic sympathomimetic
(partial agonist)
activity. The preferential effect on ß
receptors is not absolute, however, and some
inhibitory effects on ß
receptors (found chiefly in the bronchial and vascular
musculature) can be expected at higher doses.
PHARMACOKINETICS AND METABOLISM: In man, absorption of an oral dose is
complete.
There is a small and consistent first-pass effect resulting in an
absolute bioavailability of
89% ± 5% that is unaffected by the concomitant ingestion of food or
alcohol. Mean
peak blood concentrations of 21.6 ng/ml (range 16.3 to 27.9 ng/ml) are
reached
between 1.5 and 6 (mean about 3) hours after a single oral dose, in
healthy volunteers,
of 10 mg of betaxolol. Peak concentrations for 20-mg and 40-mg doses
are 2 and 4
times t
                                
                                Read the complete document
                                
                            

Search alerts related to this product